← Leaderboards
Daniel Benjamin
Duke University
$1,028,889
Attributed
$1,028,889
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $385.6K · FY2020–24$500K$375K$250K$125K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$1,028,889 · 1
By mechanism
N01$1,028,889 · 1
Top collaborators
No co-investigators on record.
Most similar at Duke University
Same institution · by research overlap
- Michael Barry Kastan$65,974,699
- Kathleen Mullan Harris$60,779,304
- Christoph Hornik$12,153,670
- Herbert Kim Lyerly$48,598,090
- Michael Cohen-Wolkowiez$47,908,561
Others in their field
Other Emerging Leaders on “Safety”
- Beth Baseler · Leidos Biomedical Research, Inc.$225,257,316
- Kimberly Smith · Ppd Development Lp$122,008,792
- Klaus Romero · Critical Path Institute$90,404,592
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$75,904,237
- Yunda Huang · Fred Hutchinson Cancer Center$70,809,823
- Leonard Freedman · Leidos Biomedical Research, Inc.$64,938,611
Research focus
SafetyPharmaceutical PreparationsInfantLactationExposure ToParticipantBreastfed InfantMaternal ObesityHuman MilkEvaluationData CollectionCaregiversMinimal Risk StudyOff-PatentBloodDrug ExposureAnti-Retroviral AgentsDrug KineticsDesignBiologicalFecesGeneticDoseEnrollment
Grant awards (3)
NICHD PEDIATRIC AND MATERNAL RESOURCE CENTER: BRIDGING PHARMACOLOGY AND THE REAL WORLD - BPCA PTN$343,265
N01 · FY2024 · HD · contact PI
PHARMACOKINETIC AND SAFETY OF ANTIRETROVIRAL AND RELATED DRUGS IN LACTATING WOMEN AND BREASTFED INFANTS STUDY$300,001
N01 · FY2023 · HD · contact PI
PHARMACOKINETIC AND SAFETY OF ANTIRETROVIRAL AND RELATED DRUGS LACTATING WOMEN AND BREASTFED INFANTS STUDY$385,623
N01 · FY2020 · HD · contact PI